The company offers test for markers for cancer treatment for both lung and colon cancer to help determine which treatment plans will benefit the patient. The use of genetic testing is getting very specific as well as the tests and expressions.
“RGI has determined ranges of ERCC1 expression values that will optimally classify tumors into categories of low and high probability of response to platinum-based therapy. The ERCC1 test can help doctors to make informed decisions about whether to recommend platinum versus non-platinum therapies for NSCLC.”
NEW YORK (GenomeWeb News) – Response Genetics said today that it intends to triple the size of its sales force in response to higher demand for its ResponseDx genetic testing services.
According to Response Genetics, it has sold more than 500 of its ResponseDx: Lung and ResponseDx: Colon tests since their launch in September 2008. It said that sales figures have surpassed the firm’s initial goals. The firm also noted that it is experiencing a reorder rate of more than 90 percent for the PCR-based tests, which are offered through Response Genetics’ CLIA-certified lab and through NeoGenomics Laboratories, which inked a deal in September to offer the tests.
GenomeWeb News: Response Genetics to Triple Size of Sales Force
0 comments :
Post a Comment